* USA: Incyte Corporation is the Marketing Autorization Holder (MAH).
Following tablet strengths are commercialized by Incyte in the USA : 5mg, 10mg, 15mg, 20mg and 25 mg.
Welcome to the JAKAVI Product Website
JAKAVI is approved for use in 43 countries around the world.
JAKAVI Country-Level Websites
Below is a list of countries that host a JAKAVI website based on the local label and written in the local language. These sites are intended for Healthcare Professionals (HCPs) only. If you are an HCP from one of the countries listed below, click the link to be redirected to your country's JAKAVI website.
JAKAVI International Website
This website is intended for healthcare Professionals (HCPs) outside the US. The information on this website is not country specific and may contain information that is outside the approved indication in the country in which you are located. Please contact your local representative for local prescribing information via www.novartisoncology.com/contactus.
IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EUSmPC)
Understanding Myeloproliferative Neoplasms
MF is a rare, potentially lethal MPN characterized by constitutional symptoms, splenomegaly, and poor quality of life.
Polycythemia Vera »
PV is the most common of the Ph(-) classic MPNs. It is characterized by an increased risk of cardiovascular events and severe pruritus, fatigue, and other symptoms.
ET is a rare disease characterized by thrombocytosis that often leads to cardiovascular and hemorrhagic complications.
Differential Diagnosis Simulator
The Myeloproliferative Neoplasm (MPN) Differential Diagnosis Simulator is designed to test your knowledge of the World Health Organization (WHO) diagnostic criteria for classic BCR-ABL -negative MPNs.View Simulator »
MPN: Clinical Presentation and Diagnosis